Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Julphar
Teva
US Army
Farmers Insurance
Johnson and Johnson
Harvard Business School
Express Scripts
Cantor Fitzgerald
Novartis
Colorcon

Generated: October 23, 2017

DrugPatentWatch Database Preview

Details for New Drug Application (NDA): 205747

« Back to Dashboard
NDA 205747 describes HUMALOG KWIKPEN, which is a drug marketed by Eli Lilly And Co and Lilly and is included in two NDAs. It is available from three suppliers. There are three patents protecting this drug. Additional details are available on the HUMALOG KWIKPEN profile page.

The generic ingredient in HUMALOG KWIKPEN is insulin lispro recombinant. There are thirty-eight drug master file entries for this compound. Three suppliers are listed for this compound. Additional details are available on the insulin lispro recombinant profile page.

Summary for NDA: 205747

Tradename:
1
Applicant:
1
Ingredient:
1
Patents:3

Pharmacology for NDA: 205747

Ingredient-typeInsulin

Suppliers and Packaging for NDA: 205747

Tradename Generic Name Dosage NDA Application Type Supplier National Drug Code Package Code Package
HUMALOG KWIKPEN
insulin lispro recombinant
SOLUTION;SUBCUTANEOUS 205747 NDA Eli Lilly and Company 0002-7712 0002-7712-27 2 SYRINGE in 1 CARTON (0002-7712-27) > 3 mL in 1 SYRINGE (0002-7712-01)

Summary for product number 001

Active Rx/OTC/Discontinued:RXDosage:SOLUTION;SUBCUTANEOUSStrength200 UNITS/ML
Approval Date:May 26, 2015TE:RLD:Yes
Patent:► SubscribePatent Expiration:Jun 11, 2018Product Flag?YSubstance Flag?Delist Request?
Patented Use:TREATMENT OF IRRITABLE BOWEL SYNDROME WITH DIARRHEA (IBS-D) IN ADULTS AND SYMPTOMS THEREOF.
Patent:► SubscribePatent Expiration:Jun 11, 2018Product Flag?YSubstance Flag?Delist Request?
Patented Use:TREATMENT OF IRRITABLE BOWEL SYNDROME WITH DIARRHEA (IBS-D) IN ADULTS.
Patent:► SubscribePatent Expiration:Jun 11, 2018Product Flag?YSubstance Flag?Delist Request?
Patented Use:TREATMENT OF IRRITABLE BOWEL SYNDROME WITH DIARRHEA (IBS-D) IN ADULTS AND SYMPTOMS THEREOF.


Complete Access Available with Subscription
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving leading biopharmaceutical companies globally:

Chinese Patent Office
Federal Trade Commission
UBS
McKesson
Fish and Richardson
Chubb
Mallinckrodt
Harvard Business School
Accenture
Dow

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot